As outlined, patient specific CNA signatures of PI3K-AKT-mTOR pathway related genes might add additional prognostic information in ccRCC patient management in line with recent reports on targeted therapies by Haddad and Margulis [42] and other colleagues [51]. The gene discussed is PIK3CB; the disease is nonpapillary renal cell carcinoma.